| Entries |
| Document | Title | Date |
|---|
| 20080199497 | Pharmaceutical Composition Comprising Botulinum Toxin for Treating Knee Joint Pain by Saphenous Nerve Entrapment - There is provided a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier for treating pain in the knee joint caused by saphenous nerve entrapment. The composition of the present invention is for subcutaneous injection above the medial side of the knee. | 08-21-2008 |
| 20080199498 | METHODS FOR TREATING EYE DISORDERS - The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum. | 08-21-2008 |
| 20080213311 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 09-04-2008 |
| 20080213312 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 09-04-2008 |
| 20080213313 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 09-04-2008 |
| 20080213314 | COMBINED DNA VACCINE AND BIOLOGICAL MODIFIERS FOR CANCER THERAPY - The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well as specific nucleic acid constructs that are particularly suitable for the preparation of such compositions. | 09-04-2008 |
| 20080213315 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS - A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation. | 09-04-2008 |
| 20080220020 | Transdermal Botulinum Toxin Compositions - Pharmaceutical compositions for transdermal administration of neurotoxins to a patient include a neurotoxin, such as a botulinum toxin, and an enhancing agent that facilitates absorption of the neurotoxin through the skin of the patient and does not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and may be provided in a transdermal patch. | 09-11-2008 |
| 20080220021 | Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis - The use of a topical botulinum toxin composition is disclosed for the treatment of a disorder amenable to treatment by botulinum toxin. The disorder may comprise the symptoms associated with hyperhidrosis. The topical botulinum toxin composition comprises phospholipid micelles, one or more primary stabilizers, and one or more skin penetration enhancers. | 09-11-2008 |
| 20080233151 | Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins - The invention relates to methods for protecting and/or treating a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, by administering a non-antibacterial tetracycline formulation. | 09-25-2008 |
| 20080233152 | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabilized with Polypeptide Fragments Derived from HIV-TAT - This invention relates to novel compositions of borulinum toxin that are stabilized using HIV-TAT fragments or derivatives of HIV-TAT fragments. The composition can be administered for various therapeutic, aesthetic and/or cosmetic purposes. The invention also provides method for stabilizing botulinum toxin using HIV-TAT fragments or derivatives or HIV-TAT fragments. | 09-25-2008 |
| 20080279895 | TARGETED DELIVERY OF BOTULINUM TOXIN TO THE SPHENOPALATINE GANGLION - Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection. | 11-13-2008 |
| 20080279896 | Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy - The present invention relates to a method of treating a movement disorder in a patient, the method comprising administering a medicament comprising an effective amount of chemodenervating agent to the patient, wherein the patient is subjected to a muscle stimulation therapy, for example an movement therapy or an muscle activation therapy, and the medicament is administered prior to and/or during and/or after the movement therapy and a kit for the treatment of patients suffering from movement disorders comprising a medicament comprising an effective amount of a chemodenervating agent, and a device for carrying out automated movement therapy. | 11-13-2008 |
| 20080292661 | Use of Botulinum Toxin for the Preparation of a Medicament for the Treatment of Lithiasis of Salivary Gland, Gall Bladder, Kidney, or Pancreas - The invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat a gland, organ or duct obstructed by a naturally formed stone. This method can be applied notably for salivary gland, gall bladder, kidney or pancreas stones. | 11-27-2008 |
| 20080317782 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 12-25-2008 |
| 20080317783 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 12-25-2008 |
| 20090004224 | ACTIVATABLE CLOSTRIDIAL TOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 01-01-2009 |
| 20090004225 | TOXIN COMPOUNDS WITH ENHANCED MEMBRANE TRANSLOCATION CHARACTERISTICS - The present invention relates to a compound comprising a toxin linked to a translocator. Non-limiting examples of toxins of the present invention are botulinum toxin, butyricum toxin, tetani toxins and the light chains thereof. In some embodiments, the translocator of the present invention comprises a protein transduction domain. | 01-01-2009 |
| 20090010967 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 01-08-2009 |
| 20090017071 | METHODS FOR TREATING NEUROGENIC INFLAMMATION - The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain. | 01-15-2009 |
| 20090022763 | ANIMAL PRODUCT FREE MEDIA AND PROCESSES FOR OBTAINING A BOTULINUM TOXIN - Media and processes for the fermentation of | 01-22-2009 |
| 20090028906 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in a solid form - The present invention relates to a method for providing a muscle relaxant at temperatures above 20° C., wherein said muscle relaxant is a solid dry composition comprising the neurotoxic component of botulinum toxin free of complexing proteins. | 01-29-2009 |
| 20090028907 | Botulinum toxin treatment - The invention relates to the use of a liquid or semi-solid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterised by bladder spasms (e.g. urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor sphincter, urinary retention secondary to spastic sphincter or hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis or characterised by a spasm reflex), wherein said medicament is for administration by infusion into the bladder or by other methods that do not involve injection into the bladder wall. | 01-29-2009 |
| 20090028908 | METHODS FOR TREATING NEUROGENIC INFLAMMATION - The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain. | 01-29-2009 |
| 20090041805 | BOTULINUM TOXIN FOR TREATING POSTHERPETIC NEURALGIA - Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a | 02-12-2009 |
| 20090041806 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY - Methods of treating spasticity by administering a colonically absorbable prodrug of a GABA analog having antispastic activity that is not directly mediated by the GABA | 02-12-2009 |
| 20090060953 | Methods for using tetanus toxin for beneficial purposes in animals (mammals) - Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided. | 03-05-2009 |
| 20090068227 | Use of neurotoxin therapy for treatment of urologic and related disorders - The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 03-12-2009 |
| 20090087457 | Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins - Improved formulations for transdermal delivery of | 04-02-2009 |
| 20090087458 | ACTIVATABLE RECOMBINANT NEUROTOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 04-02-2009 |
| 20090087459 | METHODS FOR TREATING EYE DISORDERS - The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum. | 04-02-2009 |
| 20090104234 | METHODS OF TREATING CHRONIC NEUROGENIC INFLAMMATION USING MODIFIED CLOSTRIDIAL TOXINS - The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such modified Clostridial toxins and compositions. | 04-23-2009 |
| 20090117157 | METHODS OF TREATING UROGENITAL-NEUROLOGICAL DISORDERS USING MODIFIED CLOSTRIDIAL TOXINS - The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions. | 05-07-2009 |
| 20090123497 | CHROMATOGRAPHIC METHOD AND SYSTEM FOR PURIFYING A BOTULINUM TOXIN - Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium. | 05-14-2009 |
| 20090123498 | TREATMENT OF POST-STROKE MUSCLE PAIN - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 05-14-2009 |
| 20090148476 | Chemodenervating pharmaceutical as anti-inflammatory agent - Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation. | 06-11-2009 |
| 20090155314 | Dermal filler - Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin. | 06-18-2009 |
| 20090186052 | USE OF BOTULINUM TOXIN FOR PORLONGED LOCAL DESENSITIZATION - The invention concerns the use or a fragment of botulinum toxin having said toxin activity for preparing a medicine for reversibly desensitizing an area of the skin, said skin area being designed to receive injections. Said injections can be related, for example, to repeated delivery of insulin, growth hormones or other medicines in injectable form. | 07-23-2009 |
| 20090202591 | LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS - Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain. | 08-13-2009 |
| 20090232849 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Compositions and a method for sensitizing a cancer for treatment by cytotoxic therapy is disclosed. The method includes the step of administering to the cancerous tissue or cells a pharmaceutical composition containing a | 09-17-2009 |
| 20090232850 | THERAPEUTIC TREATMENTS USING BOTULINUM NEUROTOXIN - Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis. | 09-17-2009 |
| 20090232851 | SIMULTANEOUS, SEPARATE OR SEQUENTIAL THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN AND OF AT LEAST ONE OPIATE DERIVATIVE - The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders. | 09-17-2009 |
| 20090252764 | SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXIN - The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull. | 10-08-2009 |
| 20090263426 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 10-22-2009 |
| 20090274729 | MEDIA FOR CLOSTRIDIUM BACTERIUM AND PROCESSES FOR OBTAINING A CLOSTRIDIAL TOXIN - Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing | 11-05-2009 |
| 20090304748 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS | 12-10-2009 |
| 20090317426 | METHOD FOR TREATING KNEE JOINT PAIN CAUSED BY SAPHENOUS NERVE ENTRAPMENT - A method using a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier to treat pain in the knee joint caused by saphenous nerve entrapment. The composition of the present invention is for subcutaneous injection above the medial side of the knee. | 12-24-2009 |
| 20090324647 | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use - The present invention provides compositions that contain botulinum toxin and a hyaluronidase, and that lack human or recombinant serum albumin. The present invention also provides methods of administering the pharmaceutical composition to a subject in need thereof. | 12-31-2009 |
| 20100021502 | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT - This invention relates to novel compositions of botulinum toxin that are stabilized using HTV-TAT fragments or derivatives of HTV-TAT fragments. The composition can be administered for various therapeutic, aesthetic and/or cosmetic purposes. The invention also provides method for stabilizing botulinum toxin using HIV-TAT fragments or derivatives or HIV-TAT fragments. | 01-28-2010 |
| 20100028385 | TREATMENT OF EXCESS CERUMEN SECRETION - Presently descibed are methods useful in treating outer ear conditions generally associated with the secretion of cerumen. The methods comprise the step of locally administering a therapeutically effective amount of neurotoxin such as a botulinum toxin to the ear canal of a patient. The conditions to be treated are generally associated with excess secretion of cerumen or the build-up of cerumen in the ear canal of a patient. Such conditions can include, but are not limited to, conductive hearing loss, pain and cough, for example. | 02-04-2010 |
| 20100034853 | Compositions of activated botulinum toxin type B - The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked. | 02-11-2010 |
| 20100034854 | Compositions of activated botulinum holotoxin type B (150 KD) - The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 75% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention also relates to a process of stripping botulinum toxin type B, comprising the stages of: cell growth, activation, purification, and dilution; wherein at least one dissociating reagent is administered to a volume of said botulinum toxin type B; and wherein said dissociating reagent administered increases the levels of stripped botulinum toxin type B to at least 75%. | 02-11-2010 |
| 20100055133 | PHARMACEUTICAL COMPOSITIONS - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonlus, dystoniia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 03-04-2010 |
| 20100062024 | Biologically Active Hemagglutinin From Type A Clostridium Botulinum and Methods of Use - An isolated, biologically active 33 kDa hemagglutinin purified from the type A | 03-11-2010 |
| 20100068231 | Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent - The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof. | 03-18-2010 |
| 20100068232 | Methods for treating skin lines and wrinkles and improving skin quality - Methods and compositions for improving skin quality are disclosed. The methods include applying a solution of about 20-30% pre-wetting agent, such as hyaluronic acid, and/or Botulinum toxin to a skin surface with concurrent particle-free dermabrasion treatment, such as particle-free microdermabrasion treatment. These methods lead to significant improvement in the treatment of skin aging. Compositions for improving skin quality are also disclosed. These compositions comprise a pre-wetting agent and a Botulinum toxin agent. | 03-18-2010 |
| 20100086567 | Botulinum toxin therapy for prevention of anastamotic thrombosis in free tissue transfer - An effective, long lasting, non-systemic drug administration protocol for preventing vascular vasospasm and vessel thrombosis in free tissue transplantation. In a free flap procedure, after the recipient vein and artery (vascular pedicle) are divided, the recipient artery and vein are pretreated with a local injection of | 04-08-2010 |
| 20100092517 | Dose and localization of botulinum toxins in skin and muscle - A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight. | 04-15-2010 |
| 20100098727 | METHODS FOR TREATING EYE DISORDERS - Methods of treating an eye disorder are disclosed. Particular methods comprise a step of locally administering a | 04-22-2010 |
| 20100104602 | Neurotoxin therapy for postprandial hyperglycemia - Botulinum toxin is increasingly being injected into visceral smooth muscle for a variety of indications. The present invention discloses intragastric administration of botulinum toxin to delay gastric emptying with the aim of inducing satiety and promoting weight-loss. The present invention also discloses the effects of intragastric administration of Botulinum toxin in reducing post-prandial hyperglycemia in patients suffering from Diabetes Mellitus. | 04-29-2010 |
| 20100112005 | Compositions of activated botulinum toxin type B - The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of overactive or neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. | 05-06-2010 |
| 20100112006 | Compositions of activated botulinum holotoxin type B (150 kD) - The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 99% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. | 05-06-2010 |
| 20100124559 | Early Treatment and Prevention of Increased Muscle Tonicity - Described herein are methods of preventing, modulating and treating spasticity and maladaptive neuronal plasticity in patients having upper motor neuron lesions or have had a traumatic central nervous system event by early intervention methods. The methods comprise the step of administering a therapeutically effective amount of a botulinum toxin or derivative thereof to least a portion of a 1A sensory afferent of at least one muscle prior to development of spasticity or maladaptive neuronal plasticity becomes clinically apparent. The therapeutically effective amount of botulinum toxin administered to the 1A afferent of the muscle does not substantially affect the Golgi tendons therein. | 05-20-2010 |
| 20100143413 | APPARATUS AND METHOD FOR TREATING A NEUROMUSCULAR DEFECT - A method is provided for treating a neuromuscular defect in a subject. One step of the method includes locating a target nerve. After locating the target nerve, a treatment probe is provided. The treatment probe includes an elongated body member having a proximal end portion and a distal end portion. The distal end portion includes an energy delivery mechanism for stimulating or ablating the target nerve, a monitoring mechanism, and a fluid aspiration/delivery mechanism. Next, the target nerve is verified as an appropriate target for ablation by stimulating and then monitoring the target nerve via the energy delivery mechanism and the monitoring mechanism, respectively. After verifying the target nerve, a tumescent fluid is injected into the tissue surrounding the target nerve. An electric current is then delivered to the energy delivery mechanism to substantially ablate the target nerve. | 06-10-2010 |
| 20100158950 | USE OF TETANUS TOXIN TO AMPLIFY INADEQUATE VOLUNTARY MUSCLE CONTRACTION OR TO IMPROVE MUSCLE TONE IN AN ANIMAL ACTIVELY VACCINATED AGAINST THE TOXIN AND A REGIMEN FOR TREATMENT - A method of improving muscle movement, contraction and/or tone in an animal is provided. The method is carried out by administering tetanus toxin to the muscle of an animal has already been vaccinated against tetanus toxin. The toxin is administered in an amount sufficient to improve muscle movement, contraction and/or tone. The method may be used to treat patients with impaired muscle function, e.g due to compromise of the central nervous system (for example, due to stroke or spinal cord injury) or due to muscle atrophy (for example, due to immobilization after an injury). A regimen for dosage escalation of tetanus toxin is also provided. | 06-24-2010 |
| 20100158951 | Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition - The disclosure provides a method of preparing an immunologically-active adjuvant-bound freeze dried vaccine composition. A specific embodiment provides a stable vaccine composition comprising an aluminum-salt adjuvant, a recombinant | 06-24-2010 |
| 20100172939 | Treating neoplasms with neurotoxin - The present invention provides a method of treating a neoplasm using a neurotoxin, preferably botulinum toxin. Neurotoxin administered around a neoplasm acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze neoplastic cells through efferent channels leaving the neoplasm to distant sites. The present invention also provides a method of administering botulinum toxin at sites distant from the neoplasm, thereby enhancing cellular and humoral immunologic functions, which further contribute to neoplastic cell death. Following administration of botulinum toxin around or distant to a neoplasm as described herein, local, regional, and distant spread of neoplastic cells is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other diseases that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV. | 07-08-2010 |
| 20100172940 | TREATMENT OF SOFT TISSUE INJURY USING HYALURONIC ACID AND BOTULINUM TOXIN - There is provided a method for supporting soft tissue in a mammal. The method may in aspects treat acutely or chronically injured soft tissue in an animal or human, the method comprising administering a therapeutically effective amount of HA and botulinum toxin in combination around the injured soft tissue. The method is useful for the treatment of sprain and strain in an animal such as a human. | 07-08-2010 |
| 20100196421 | GENETICALLY ENGINEERED CLOSTRIDIAL GENES, PROTEINS ENCODED BY THE ENGINEERED GENES, AND USES THEREOF - The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed. | 08-05-2010 |
| 20100209456 | TREATING NEOPLASMS WITH NEUROTOXIN - The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV. | 08-19-2010 |
| 20100266638 | HEADACHE TREATMENT METHOD - Herein disclosed are methods for treating headache, such as a chronic migraine for example, by administration of | 10-21-2010 |
| 20100272754 | BOTULINUM TOXIN ADMINISTRATION TO TREAT VARIOUS CONDITIONS - Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a | 10-28-2010 |
| 20100278867 | Use of botulinum toxin for the treatment of chronic facial pain - The present invention includes a method of treating pain caused by neuralgia comprising administering botulinum toxin to an afflicted area of a patient. The pain may be caused by trigeminal neuralgia or be associated with dental extraction or reconstruction, and may be facial pain. The neuralgia may be associated with compressive forces on a sensory nerve, intrinsic nerve damage, demyelinating disease, a genetic disorder, a metabolic disorder, central neurologic vascular disease, or trauma. The present invention also includes a method of treating post-operative incisional wound pain comprising administering botulinum toxin to an afflicted area of a patient. The post-operative incisional wound pain may be associated with medical treatments selected from the group consisting of sinus surgery, removal of an eye, temporal mandibular joint surgery, parotid gland extraction and resection, craniotomy for removal of an intracranial tumor, intra-ocular surgery, acoustic neuroma surgery, reconstructive procedures after tumor resection, radiation therapy for the treatment of cancer, skull base surgery, orbitectomy, facial bone removal, muscle removal, skin removal, and construction of myocutaneous flaps. | 11-04-2010 |
| 20100278868 | Codon-Optimized Dna Molecules Encoding the Receptor Binding Domains of Clostridium Difficile Toxins A and B, and Methods of Use Thereof - In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of | 11-04-2010 |
| 20100291151 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR - The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5-HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 11-18-2010 |
| 20100297180 | BOTULINUM NEUROTOXIN VACCINE - The invention provides compositions comprising an antigenic botulinum neurotoxin serotype E (BoNT/E) peptide, wherein the peptide has improved solubility and thus improved ability to stimulate an immune response against BoNT/E holotoxin. The composition may be used as part of a multivalent vaccine regimen via coordinated use with non-serotype E BoNT peptides, such as one or more BoNT/A and/or BoNT/B peptides. It further provides processes for manufacturing said BoNT/E peptide. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a BoNT/E and optionally one or more non-serotype E BoNT peptides such as one or more BoNT/A and/or BoNT/B peptides. | 11-25-2010 |
| 20100297181 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ - The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in sensory organ. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, one or more other active ingredients that are useful for treating epilepsy, mental disorders and/or deficits in sensory organ. | 11-25-2010 |
| 20100297182 | Injectable Amino-acid Composition - An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness. | 11-25-2010 |
| 20100330123 | ALBUMIN-FREE BOTULINUM TOXIN FORMULATIONS - This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations. | 12-30-2010 |
| 20110038892 | COMPLEXING SYSTEM - The invention relates to a complexing system comprising two polypeptide helices derived from a SNAP protein; one polypeptide helix derived from syntaxin; one polypeptide helix derived from synaptobrevin or a homolog thereof; and one or more cargo moieties attached to the polypeptide helices, wherein the four polypeptide helices can form a stable SNARE complex. The invention also relates to a method of producing the complexing system and the use of the complexing system. | 02-17-2011 |
| 20110038893 | THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN ASSOCIATED WITH DIABETIC NEUROPATHY - The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration. | 02-17-2011 |
| 20110045025 | Pharmaceutical Compositions Containing Clostridium Difficile Toxoids A and B - This invention relates to compositions including | 02-24-2011 |
| 20110052636 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a | 03-03-2011 |
| 20110076305 | EXTRACELLULAR MATRIX MATERIALS AS VACCINE ADJUVANTS FOR DISEASES ASSOCIATED WITH INFECTIOUS PATHOGENS OR TOXINS - Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvant may also be described as a heterologous acellular collagenous tissue preparation. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal. | 03-31-2011 |
| 20110091503 | Therapeutic composition with a botulinum neurotoxin - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 04-21-2011 |
| 20110091504 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from | 04-21-2011 |
| 20110091505 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from | 04-21-2011 |
| 20110104206 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS - The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically. | 05-05-2011 |
| 20110142882 | Control of blood flow in skin, subcutaneous tissue and muscle by botulinum toxin, snare protein mediating substances, and alpha adrenergic agents by either injection of transdermal delivery systems - Methods for controlling abnormal blood flow in disease states by the selective alteration of the components of microvascular flow using Botulinum A Toxin, other SNARE protein mediating agents, alpha adrenergic agents, and other compounds is heretofore unknown, whether delivered by injection, topical application, or transdermal means. The invention discloses novel methods for the control of blood flow in skin, subcutaneous tissue and muscle by botulinum toxin, snare protein mediating substances, and alpha adrenergic agents by either injection or transdermal delivery systems. | 06-16-2011 |
| 20110165195 | COMPOSITION FOR MUCOSAL ADMINISTRATION CONTAINING AGENT FOR ENHANCING MUCOSAL ABSORPTION OF PEPTIDE DRUG, AND ADMINISTRATION METHOD THEREOF - A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium | 07-07-2011 |
| 20110165196 | Method for treatment of crib biting in animals - The present invention generally relates to methods for treating cribbing behavior in animals. Benefits are obtained by administering to the animals to be treated injections of Botulinum Toxin in the sternocephalic muscle, thereby denervating these muscles and preventing cribbing behavior. | 07-07-2011 |
| 20110200639 | Botulinum toxin treatments of Depression - Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a | 08-18-2011 |
| 20110206731 | BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS - Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder. | 08-25-2011 |
| 20110243991 | PROCESS FOR PRODUCTION OF VACCINES - The invention relates to a process for the production of a vaccine against bacterial pathogens which produce an AB toxin, like | 10-06-2011 |
| 20110280909 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE - Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease. | 11-17-2011 |
| 20110293663 | Pharmaceutical botulinum toxin compositions - Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and delivery of the botulinum toxin to neural and associated tissues, as compared with available formulations of botulinum toxins, and thereby produce a beneficial clinical effect. The sequestration agents of the present invention include proteins, lipids and carbohydrates. A preferred composition of the present invention comprises a botulinum toxin and an albumin. The present invention also provides methods of treating neuromuscular diseases and pain using the disclosed compositions and methods of making the disclosed compositions. | 12-01-2011 |
| 20110318385 | ENGINEERED BOTULINUM NEUROTOXIN C1 WITH SELECTIVE SUBSTRATE SPECIFICITY - An isolated polypeptide comprising a botulinum neurotoxin C1 light chain having a modified amino acid sequence relative to the sequence of a wild-type botulinum neurotoxin C1 light chain is disclosed. The modified botulinum neurotoxin C1 light chain is capable of selectively cleaving syntaxin protein, but has substantially reduced or no activity against SNAP-25 as compared to wild type botulinum neurotoxin C1 light chain, and is thus useful as a research tool and in medical treatment. | 12-29-2011 |
| 20120021002 | GENETICALLY ENGINEERED CLOSTRIDIAL GENES, PROTEINS ENCODED BY THE ENGINEERED GENES, AND USES THEREOF - The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed. | 01-26-2012 |
| 20120039940 | METHODS FOR TREATING UTERINE DISORDERS - A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue. | 02-16-2012 |
| 20120039941 | ENGINEERED BOTULINUM NEUROTOXIN - The present invention provides a novel modified BoNT/E catalytic domain and methods of use thereof. In one embodiment, the light chain residue 224, or a residue corresponding to residue 224, of the modified BoNT/E catalytic domain has been altered to be aspartic acid or glutamic acid. The modified catalytic domain cleaves SNAP23 but does not cleave SNAP29 or SNAP47, providing novel methods of treating diseases including without limitation, asthma, CF, chronic obstructive pulmonary, gastric acid efflux and inflammation, immune disorders with a cytokine component or cancers with a cytokine component. | 02-16-2012 |
| 20120093866 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT - The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, and wherein the formulation is free of stabilizing proteins. | 04-19-2012 |
| 20120107361 | Albumin-Free Botulinum Toxin Formulations - This invention relates to | 05-03-2012 |
| 20120107362 | NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY - The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain of the neurotoxin polypeptide as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. | 05-03-2012 |
| 20120114696 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS - This disclosure relates to materials and methods for inhibiting Botulinum neurotoxin, and more particularly to materials and methods for inhibiting the zinc endopeptidase of Botulinum neurotoxin serotypes A, D and/or E (BoNTA, BoNTD and/or BoNTE). | 05-10-2012 |
| 20120114697 | TREATMENT OF HOLOCRINE GLAND DYSFUNCTION WITH CLOSTRIDIA NEUROTOXINS - Methods of using clostridial toxins and other biological agents to control holocrine gland dysfunction in humans is provided. In preferred embodiments the methods provide beneficial effects in humans. | 05-10-2012 |
| 20120141532 | Botulinum Toxin Formulation - Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects. | 06-07-2012 |
| 20120156244 | Nasal Compositions and Uses Thereof - Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions. | 06-21-2012 |
| 20120171247 | NOVEL PROTEINS WITHIN THE TYPE E BOTULINUM NEUROTOXIN COMPLEX - The invention features a polypeptide complex synthesized by bacteria of the genus | 07-05-2012 |
| 20120207787 | Animal Protein-Free Pharmaceutical Compositions - Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. | 08-16-2012 |
| 20120225094 | Treatment of Sleep Disordered Breathing with Neurotoxin - Disclosed herein are compositions of neurotoxins and methods of their use for the treatment of sleep disordered breathing. In one embodiment of the present invention, a method of treating sleep breathing disorders comprising administering a therapeutically effective amount of Clostridia neurotoxin (CnT) or light chain thereof to a mammal in need thereof is disclosed. | 09-06-2012 |
| 20120237548 | PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN - This invention relates to the use of a composition comprising a polysaccharide and a | 09-20-2012 |
| 20120244188 | Treatment of Sensory Disturbance Disorders - The present specification discloses methods of treating a sensory disturbance disorder in an individual using Targeted Endopeptidase Modulators (TEMs), compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, use of such TEMs and/or Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs in treating a sensory disturbance disorder, and use of such TEMs and Clostridial toxins in treating a sensory disturbance disorder. | 09-27-2012 |
| 20120251573 | Endopeptidase Treatment of Neuroendocrine Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a neuroendocrine disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a neuroendocrine disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating neuroendocrine disorder, use of such TEMs in treating a neuroendocrine disorder, and use of such TEMs and Clostridial toxins in treating a neuroendocrine disorder. | 10-04-2012 |
| 20120251574 | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions - The present specification discloses Clostridial neurotoxins and TEMs, compositions comprising such Clostridial neurotoxins and TEMs, methods of treating a multiple medical disorder in an individual using such compositions, use of such Clostridial neurotoxins and TEMs in manufacturing a medicament for treating a multiple medical disorder, and uses of such Clostridial neurotoxins and TEMs in treating a multiple medical disorder. | 10-04-2012 |
| 20120251575 | Endopeptidase Treatment of Involuntary Movement Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating an involuntary movement disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating an involuntary movement disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating an involuntary movement disorder, use of such TEMs in treating an involuntary movement disorder, and use of such TEMs and Clostridial toxins in treating an involuntary movement disorder. | 10-04-2012 |
| 20120251576 | Treatment of Nasal and Sinus Disorders - Disclosed herein are compositions and methods for treating nasal and sinus conditions, and symptoms thereof, with | 10-04-2012 |
| 20120315297 | Treatment of Psychological Trauma - The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof. | 12-13-2012 |
| 20130177592 | IMMUNIZATION AGAINST CLOSTRIDIUM DIFFICILE DISEASE - The invention provides active and passive immunization methods for preventing and treating | 07-11-2013 |
| 20130183344 | RECOMBINANT VACCINE AGAINST CLOSTRIDIUM PERFRINGENS INFECTION AND EPSILON TOXIN INTOXICATION - The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of | 07-18-2013 |
| 20130189307 | METHOD OF TREATING DEPRESSION - Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject. | 07-25-2013 |
| 20130224248 | FORMULATION SUITABLE FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENTS - A formulation free of protein which stabilizes pharmaceutical active proteins, peptides, or mixtures thereof in large scale production processes comprising a mixture of a hydrophilic polymer and a non-ionic detergent, and a mixture of a polyalcohol and a sugar. In some embodiments the polyalcohol is absent. | 08-29-2013 |
| 20130315957 | METHOD OF TREATING VERTIGO - The invention is a method for reducing the symptoms of vertigo. The method is performed by delivering a therapeutically effective amount of presynaptic neurotoxin, such as Botulinum Toxin A, in a pharmaceutically safe form to suitable locations around the head and neck. | 11-28-2013 |
| 20140161839 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN - The present invention relates to a compound of the following general formula (I): R | 06-12-2014 |
| 20140212456 | TREATMENT METHODS USING ATOXIC NEUROTOXIN DERIVATIVES - The present invention relates to a treatment method. This method involves contacting a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin. Contacting is carried out to treat the subject. The derivative of a Clostridial neurotoxin does not possess a cargo attachment peptide sequence at its N-terminus. | 07-31-2014 |
| 20140271717 | DEVICES CONTAINING A CHEMICAL DENERVATION AGENT AND METHODS FOR TREATING CHRONIC BACK PAIN USING CHEMICAL DENERVATION - Effective devices and methods using a chemical denervation agent are provided for treating chronic back pain. The devices and methods comprise a chemical denervation agent to degrade or to shrink at least a portion of a nerve associated with back pain e.g. basivertebral nerve of the lumbar. In some embodiments, the methods and devices are configured to immediately release an effective amount of the chemical denervation agent within 24 hours and provide sustained release of the chemical denervation agent or other therapeutic agent over a period of up to one year to treat chronic back pain. | 09-18-2014 |
| 20140370056 | Mucosal Vaccine Using Cationic Nanogel - A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route. | 12-18-2014 |
| 20160045586 | Toxoid, Compositions and Related Methods - The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods). Provided are methods of producing a | 02-18-2016 |
| 20180022784 | Clostridium Difficile Toxins a and/or B Antigen and Epitope Antibody, and Pharmaceutical Uses Thereof | 01-25-2018 |
